Published on
November 3, 2023
- 16:00 GMT
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 ...
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR …
Distribution channels:
Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry
...
